NervGen Pharma Corp. NGEN
—
1.94
(0.08)
(3.96%)
as of 25 Sep
- Market cap
- $217.2M
- P/E
- 0.0×
Follow NGEN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+3 more quarters Free account |
0.79 | 1.16 | 1.34 | 1.23 |
Net Debt/EBITDA |
1.85 | 3.45 | 2.20 | 7.12 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.29 | 0.23 | 4.89 | 0.19 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.03 | 0.02 | 0.02 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.05) | (0.06) | (0.07) | (0.04) | |
Cash per Share |
0.11 | 0.22 | 0.15 | 0.68 | |
Shareholders Equity per Share |
(0.03) | 0.03 | 0.05 | 0.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.03) | 0.03 | 0.05 | 0.14 | |
Free Cash Flow |
(3.88) | (4.44) | (5.98) | (4.09) | |
Working Capital |
(2.44) | 2.20 | 3.75 | 12.20 | |
Net Current Asset Value |
(2.44) | 2.20 | 3.75 | 12.20 | |
| Other line items | |||||
Quick Ratio |
0.73 | 1.12 | 1.09 | 1.19 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.05) | (0.06) | (0.07) | (0.04) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
— | 0.18 | 0.15 | 0.11 | |
Average Payables |
— | 3.47 | 3.71 | 3.44 | |
Average Assets |
— | 15.42 | 13.08 | 38.69 | |
Average Common Equity |
— | 2.18 | 2.50 | 5.91 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates